ClearCut Medical aims to eliminate repeat cancer surgeries, improve pathology workflow and achieve overall better outcomes for cancer patients. Initially focusing on breast conserving cancer surgery (BCS or lumpectomy), we aim to reduce the number or repeat surgeries by at least 75%, saving the medical insurance providers on average $16,000 per case.
The company was founded in 2010 and has since developed an intra-operative, mobile magnetic resonance scanner for excised tissue, which the operating surgeon uses to establish complete cancer removal in real-time, rather than having to rely on pathological confirmation weeks after the initial surgery. Pathologists use the images to better target post-operative sampling of the excised tissue for final histopathology. The device has shown high accuracy in a clinical trial recently published in a leading journal and is CE marked, FDA expected mid 2018. Start of commercialization is planned for end of 2017 focusing on breast cancer surgery, with a TAM of $1.2 billion in the US and Europe alone.